RVBA-NOVO

Novo Nordisk — full event log

Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.

← back to Data by year

2024· 16 events

New scope 3 target: 33% reduction by 2033 (2024 baseline)affects scope 3 co2eData confidence — high

Novo Nordisk set a new SBTi-aligned target to reduce absolute scope 3 emissions by 33% by 2033, using 2024 as baseline. Target covers nearly 70% of scope 3 emissions and submitted to SBTi for validation. Consistent with SBTi well-below 2.0°C pathway.

sustainability_report p.57

30% plastic footprint reduction per patient by 2033affects packaging recyclable pctData confidence — high

Set global target to reduce plastic per patient by 30% by 2033 vs 2024 baseline of 0.35 kg/patient. Includes transition to reusable devices and circular product design.

sustainability_report p.14

Nature roadmap: halt nature loss by 2033, nature-positive by 2045Data confidence — high

Formalised nature roadmap to halt loss of nature in value chain by 2033, and become nature positive by 2045. Includes water withdrawal savings, deforestation-free supply chain ambitions, biodiversity restoration.

sustainability_report p.68

Acquired three Catalent fill-finish sites for USD 11.7 billionData confidence — high

On 18 December 2024, Novo Nordisk acquired three fill-finish sites located in US (Bloomington), Italy (Anagni) and Belgium (Brussels) from Novo Holdings A/S, in connection with Novo Holdings' acquisition of Catalent Inc. About 3,500 employees included. Total cash consideration USD 11.7bn (DKK 82.1bn).

sustainability_report p.130

Restated scope 3 methodology (cats 1, 2, 4, 6)affects scope 3 co2eData confidence — high

Updated scope 3 methodology for purchased goods, capital goods, upstream transport and business travel. Cat 1 restated from 2,067 to 1,018 ktCO2e; Cat 2 from 1,315 to 303 ktCO2e in 2023. Previously overstated due to spend-based factor uncertainty. Total 2023 scope 3 restated from 1,836 to 1,743 ktCO2e.

sustainability_report p.57

Lost-time accident frequency calculation harmonised to international standardaffects h s lost time injury rateData confidence — high

Changed from 1,600 to 2,000 working hours per FTE per year for accident rate calculation, in line with international standard. Comparatives restated.

sustainability_report p.85

First Sustainability Statement under CSRD with double materiality assessmentData confidence — high

2024 is first Sustainability statement prepared under EU CSRD requirements, including double materiality assessment identifying patient protection, climate change, resource use and circular economy, and own workforce as essential topics.

sustainability_report p.47

Scope 3 baseline reset to 2024 for new 2033 targetaffects scope 3 co2eData confidence — high

Updated scope 3 decarbonisation roadmap with 2024 as new baseline (1,493 ktCO2e for target scope). Previously baseline was 2019. Target covers ~70% of scope 3 in line with SBTi provisions.

sustainability_report p.57

Updated scope 3 decarbonisation roadmap expanding scopeData confidence — high

Updated scope 3 roadmap expanded from operations and transportation to cover operations and value chain globally. With projected growth, anticipate overall growth in GHG emissions until 2030 before decline.

sustainability_report p.55

Carbon removals to neutralise residual emissions beyond 2033Data confidence — high

Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of baseline emissions toward net zero 2045, in line with SBTi requirements and IPCC guidance. Exploring opportunities involving both nature-based and technology-based solutions. Estimates residual emissions after decarbonisation levers to be 150 thousand tonnes CO2e. Does not currently use biodiversity offsets as part of nature roadmap.

sustainability_report p.55

Primary: Renewable electricity & heat/steam electrification (Scope 1+2)Data confidence — high

Decarbonising own operations through 100% renewable electricity sourcing, energy efficiency programmes (e.g. district cooling ring at Kalundborg expected to save >20,000 MWh/year from 2026), converting steam and heat to renewable energy, electrifying processes, and covering natural gas consumption with biogas certificates. In 2024, energy savings of 13,740 MWh achieved. Target: zero scope 1 and 2 emissions by 2030, with 131 ktCO2e of expected reductions across scope 1+2 by 2030.

sustainability_report p.56

Dependent: Supplier renewable energy transition (Scope 3 cat 1 & 2)Data confidence — high

Working with suppliers to convert tier 1 suppliers to renewable energy. More than 1,800 suppliers have committed to transition to renewable power. Categories 1 (purchased goods) and 2 (capital goods) account for ~80% of scope 3 emissions. Also converting to lower-carbon raw materials and feedstock for device and drug manufacturing, lower-carbon construction materials, and process optimisations to lower material use.

sustainability_report p.56

Dependent: Distribution decarbonisation: SAF, SMF and low-carbon road freightData confidence — high

Lowering distribution emissions through: (1) air freight reduction by converting upstream air freight to sea, plus Sustainable Aviation Fuel (SAF) via long-term off-take agreements; (2) sea freight using Sustainable Marine Fuel (SMF) in upstream distribution; (3) low-carbon road freight solutions both upstream and downstream. Targeting scope 3 categories 4 and 9 to 2033.

sustainability_report p.56

Primary: Reusable injection devices & plastic footprint reductionData confidence — high

Targeting 30% reduction in plastic per patient by 2033 (baseline 0.35 kg/patient 2024). Transitioning from disposable to reusable devices, developing once-weekly rather than once-daily formulations. Scaling ReMed device take-back scheme to 7 markets with >4 million returned pens. Lower-carbon plastic partnership using e-methanol begins production in 2025.

sustainability_report p.14

Primary: Lower-carbon materials & feedstock substitutionData confidence — high

Switching to low-carbon materials and feedstock across production network including device materials, drug manufacturing inputs, and lower-carbon construction materials. Industrial partnership to purchase e-methanol to produce lower-carbon alternative to one of Novo Nordisk's top two plastic types, with production starting 2025. Explore use of low-impact glucose alternatives in production processes.

sustainability_report p.14

100% renewable electricity at all production sitesData confidence — high

Novo Nordisk has transitioned to 100% renewable electricity for all production sites since 2020, using Power Purchase Agreements (PPAs), Renewable Electricity Certificates (RECs), and Guarantees of Origin (GOs). Almost all of Novo Nordisk's electricity consumption was procured from renewable sources in 2024. Affiliates reached 99% coverage. Renewable energy accounted for 54% of total energy consumption. More than 1,800 suppliers have committed to transitioning to renewable power. Plans to electrify heat and steam where possible and cover US natural gas consumption with biogas certificates.

sustainability_report p.56